I have written to the National Press Foundation stating my concern with the fact that they have accepted funding from the drug company Pfizer to offer journalism fellowships on cancer issues.
I read about this in an e-newsletter sent by the Society of Professional Journalists (SPJ). The SPJ newsletter wrote that “Fifteen fellowships will be awarded and they all include lodging, airfare and most meals.”
I wrote to the SPJ president about my concerns, stating that “I don’t think SPJ should be encouraging journalists to take these pharma-funded all-expenses-paid trips by promoting them in the newsletter.”
I remind SPJ that its own code of ethics includes these clauses:
Journalists should:
—Avoid conflicts of interest, real or perceived.
— Remain free of associations and activities that may compromise integrity or damage credibility.
— Refuse gifts, favors, fees, free travel and special treatment, and shun secondary employment, political involvement, public office and service in community organizations if they compromise journalistic integrity.
If taking free airfare, lodging and meals from a drug company whose work you cover isn’t at least a perceived conflict of interest, I don’t know what it is. And I don’t think SPJ should promote events in its own newsletter that, in my reading, invites journalists to violate the SPJ code.
More on SPJ in a moment.
I also wrote to the National Press Foundation and had a long e-mail exchange with its president. In a nutshell, he defended their acceptance of the drug company money – just as he did when Merrill Goozner wrote about his concerns with NPF’s handling of another drug company-sponsored journalism event last fall. Or just as he did when Duff Wilson – then of the Seattle Times but now of the New York Times – wrote about NPF taking pharma money four years ago.
Now back to SPJ.
At its national conference in Indianapolis this August, SPJ will offer a tour of the Eli Lilly drug company corporate headquarters and “a professional development session on the reporting of mental health issues.” SPJ invites journalists on its website, with: “you can participate in a networking reception with Lilly leaders to learn more about Lilly’s history—and future—from the very individuals who are working to shape it.”
Lilly makes:
* Cymbalta for depression and “generalized anxiety disorder”
* Prozac
* and Zyprexa for schizophrenia and bipolar disorder
Why don’t journalists see any problem with these arrangements? Actually journalists did see problems with such activities– at one time. The ones who wrote the SPJ code of ethics. Something about “Refuse gifts, favors, fees, free travel and special treatment….avoid conflicts real or perceived…etc.”
In their article, “Who’s Watching the Watchdogs?” in the BMJ on November 19, 2008, Schwartz, Woloshin and Moynihan wrote:
“As watchdogs the media play a vital role in highlighting interconnections between doctors, researchers, and the drug industry. But who watches the watchdogs?
Financial ties between medical journalists and for-profit companies they cover in their reporting have received little attention in the media or from the research
community. Such ties warrant scrutiny, not least because many of us first learn about new treatments from the news media, and these reports can affect the way the public uses health care.”
The authors conclude:
“Training and further education of medical journalists should not be funded by the healthcare industries that the journalists cover.”
We urge the National Press Foundation and the Society of Professional Journalists to re-evaluate their policies.
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Charles Hodges MD
January 14, 2010 at 11:32 amThe reason why jounralists dont see the conflict is the same reason why doctors eat free lunches and take speaking fees from drug companies and go to free CME meetings. They do not understand the relationship between gifts and opinion. “the bribe perverts justice” is somewhere in proverbs. Unrestricted grants in research are the same thing.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like